Javier Rodriguez, Chief Legal Officer, Senior Vice President and Corporate Secretary of BioXcel Therapeutics, Inc. (NASDAQ:BTAI), recently sold shares of the company's common stock totaling $7,111. The transactions followed the vesting of restricted stock units (RSUs).
The sale comes as BTAI trades at $1.13, near its 52-week low of $1.01 and down 86% from its 52-week high of $8.08.
On May 20, 2026, Mr. Rodriguez disposed of 6,560 shares at a weighted average price of $1.084 per share, with prices ranging from $1.07 to $1.09. The sale was executed under a Rule 10b5-1 trading plan adopted on February 3, 2026 to cover taxes associated with RSU vesting. According to Bond.az analysis, the stock appears slightly undervalued at current levels.
Earlier, on May 4, 2026, 17,500 RSUs held by Mr. Rodriguez vested. These were part of a grant of 70,000 RSUs issued on January 1, 2026. The vesting schedule stipulates that 25% vested on the six-month anniversary of November 4, 2025, with the remaining 75% vesting in three equal installments every six months, subject to continuous employment.
Following these transactions, Mr. Rodriguez directly owns 26,803 shares and holds 52,500 unvested RSUs.
In other recent news, BioXcel issued warrants to lenders and is preparing to unveil its commercial launch strategy for IGALMI. The company has begun enrolling patients in a Phase 2a trial for BXCL501. H.C. Wainwright reiterated a Buy rating with a $5.00 price target.
